Introduction
cancer, ovarian carcinoma, hypoxemia, tumour, platinum-resistant ovarian cancer
CANCER, EPITHELIAL OVARIAN CANCER, TUMOUR, OVARIAN CARCINOMA
Epithelial ovarian cancer remains the gynaecological malignancy with the highest mortality being the seventh most common cancer in women worldwide (Sung et al. In patients with platinum-resistant ovarian cancer, the randomized phase 3 AURELIA trial, demonstrated for the first time an improvement of progression-free survival (PFS) incorporating bevacizumab, a VEGF-inhibitor, to single-agent chemotherapy selected by investigator’s choice (weekly paclitaxel, pegylated liposomal doxorubicin [PLD], or topotecan), while the effect on overall survival remained not significant (Pujade-Lauraine et al. Pazopanib, a non-selective oral multi-kinase inhibitor limits tumour growth by targeting angiogenesis, resulted by hypoxemia of the tumour microenvironment, via inhibition of different enzymes of the VEGF-receptor family (Schutz et al. Topotecan, the well-known topoisomerase I inhibitor is one of the established treatment options for recurrent platinum-resistant ovarian carcinoma (Sehouli et al. 